CL250514-17610, 6A5
The cell line is not validated yet.
MILi007-A
General
iPSC Line |
|
| hPSCreg name | MILi007-A |
| Cite as: | MILi007-A |
| Alternative name(s) |
CL250514-17610, 6A5
|
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines | No similar lines found. |
| Last update | 6th August 2026 |
| User feedback | |
Provider |
|
| Generator |
Miltenyi Biotec B.V. & Co. KG (MIL)
Contact:
Miltenyi Biotec B.V. & Co. KG (MIL) |
| Owner | Miltenyi Biotec B.V. & Co. KG (MIL) |
| Distributors | |
| Derivation country | Germany |
External iPSC Databases |
|
| BioSamples | SAMEA123006223 |
General iPSC Information |
|
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 45-49 |
| Ethnicity | European, white |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA123006222 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | No |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Klinisches Ethikkomitee (KEK) Universitätsklinikum Bonn |
| Approval number | Ref. No. 311/14 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
iPSC Derivation
General |
|
| Source cell type |
A connective-tissue cell of mesenchymal origin that secretes proteins and especially molecular collagen from which the extracellular fibrillar matrix of connective tissue forms.
|
| Source cell origin |
1: The proximal segment of the vertebrate hind limb extending from the hip to the knee and supported by a single large bone. 2: The segment of the leg immediately distal to the thigh in a bird or in a quadruped in which the true thigh is obscured.
|
| Age of donor (at collection) | 45-49 |
| Collected in | 2024 |
| Passage number reprogrammed | 2 |
Reprogramming method |
|
| Vector type | None |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
mRNA
|
| mRNA | |
Other |
|
| Selection criteria for clones | Cell sorting was performed using a closed, cartridge-based microfluidic system (positive selection of TRA-1-60+ cells) |
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
iPSC Culture Conditions
| Surface coating | Laminin | ||||||
| Feeder cells |
No |
||||||
| Passage method |
Enzymatically
TrypLE
|
||||||
| O2 Concentration | 20 % | ||||||
| CO2 Concentration | 5 % | ||||||
| Medium |
Other medium:
Base medium: StemMACS™ PSC-Brew XF, human
Main protein source: Serum concentration: % Supplements
|
||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this iPSC line? | Yes |
||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this iPSC line? | No |
||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this iPSC line? | Yes |
iPSC Characterisation
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| SOX2 |
Yes |
|||||
| SSEA-1 |
No |
|||||
| SSEA-4 |
Yes |
|||||
| TRA 1-60 |
Yes |
Differentiation Potency
In vitro directed differentiation
Morphology
In vitro spontaneous differentiation
| Marker | Expressed |
| CD140b (PDGFRB) |
Yes |
| CD144 (CDH5) |
Yes |
Morphology
In vitro directed differentiation
Morphology
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
|
Other Genotyping (iPSC Line) |
|
Login to share your feedback, experiences or results with the research community.